Autoimmune gastritis, with or without pernicious anemia: epidemiology, risk factors, and clinical management

Sheila D Rustgi, Priyesha Bijlani, Shailja C Shah, Sheila D Rustgi, Priyesha Bijlani, Shailja C Shah

Abstract

Autoimmune gastritis (AIG) is a chronic immune-mediated, inflammatory condition that involves the destruction of the gastric oxyntic mucosa through the autoimmune-mediated loss of parietal cells, with replacement by atrophic and metaplastic tissue. Diagnosing AIG is important, given the need for ongoing clinical management and vigilance with respect to downstream complications, the most serious of which is gastric adenocarcinoma. Other clinical consequences include gastric neuroendocrine tumors, consequences related to decreased gastric acid and decreased intrinsic factor due to parietal cell destruction and antibodies against intrinsic factor (e.g. micronutrient deficiencies), as well as concomitant autoimmune disorders. Considering the prevalence of AIG and the potential for severe clinical outcomes, it is important to engage in efforts to reduce practice pattern variability related to diagnosis and management. Accordingly, herein, we review of the epidemiology, pathogenesis, clinical presentation of AIG, including both gastric and extragastric manifestations, and provide an overview of clinical management.

Keywords: Helicobacter pylori; atrophic gastritis; carcinoid; gastric neoplasm; intestinal metaplasia; iron deficiency; neuroendocrine tumors; vitamin B12 deficiency.

Conflict of interest statement

Conflict of interest statement: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

© The Author(s), 2021.

Figures

Figure 1.
Figure 1.
Endoscopic view of type-1 gastric neuroendocrine tumor on background of atrophic gastritis. The typical endoscopic features of atrophic gastritis are apparent, including loss of rugal folds and pallorous-appearing gastric mucosa; not as appreciated here is the increased prominence of submucosal blood vessels in the gastric body due to the thinned gastric mucosa. Endoscopic image is courtesy of Michelle K Kim, MD PhD.
Figure 2.
Figure 2.
(a) Histopathological features of autoimmune gastritis (H&E stain, 100×, oxyntic mucosa). As characteristic of autoimmune gastritis, there is absence of parietal and chief cells. These are replaced by intestinal metaplasia and pseudopyloric metaplasia. There is background chronic inflammation. (b) Histopathologic image of type-I gastric neuroendocrine tumor. The tumor cells are well differentiated as evidenced by monomorphic round nuclei. These appear as “nests” infiltrating the lamina propria. Chromogranin A stain could be used to confirm neuroendocrine differentiation (stain not shown). Images are courtesy of Dr M Blanca Piazuelo.
Figure 3.
Figure 3.
Clinical and histological manifestations of autoimmune gastritis.

References

    1. Judd LM, Gleeson PA, Toh BH, et al.. Autoimmune gastritis results in disruption of gastric epithelial cell development. Am J Physiol 1999; 277: G209–G218.
    1. Strickland RG, Mackay IR. A reappraisal of the nature and significance of chronic atrophic gastritis. Am J Dig Dis 1973; 18: 426–440.
    1. Zhang H, Jin Z, Cui R, et al.. Autoimmune metaplastic atrophic gastritis in Chinese: a study of 320 patients at a large tertiary medical center. Scand J Gastroenterol 2017; 52: 150–156.
    1. Park JY, Cornish TC, Lam-Himlin D, et al.. Gastric lesions in patients with autoimmune metaplastic atrophic gastritis (AMAG) in a tertiary care setting. Am J Surg Pathol 2010; 34: 1591–1598.
    1. Andres E, Serraj K. Optimal management of pernicious anemia. J Blood Med 2012; 3: 97–103.
    1. Miceli E, Vanoli A, Lenti MV, et al.. Natural history of autoimmune atrophic gastritis: a prospective, single centre, long-term experience. Aliment Pharmacol Ther 2019; 50: 1172–1180.
    1. Carmel R, Johnson CS. Racial patterns in pernicious anemia. Early age at onset and increased frequency of intrinsic-factor antibody in black women. N Engl J Med 1978; 298: 647–650.
    1. Carmel R, Johnson CS, Weiner JM. Pernicious anemia in Latin Americans is not a disease of the elderly. Arch Intern Med 1987; 147: 1995–1996.
    1. Notsu T, Adachi K, Mishiro T, et al.. Prevalence of autoimmune gastritis in individuals undergoing medical checkups in Japan. Intern Med 2019; 58: 1817–1823.
    1. Wolf EM, Plieschnegger W, Geppert M, et al.. Changing prevalence patterns in endoscopic and histological diagnosis of gastritis? Data from a cross-sectional Central European multicentre study. Dig Liver Dis 2014; 46: 412–418.
    1. Raess PW, Baird-Howell M, Aggarwal R, et al.. Vertical sleeve gastrectomy specimens have a high prevalence of unexpected histopathologic findings requiring additional clinical management. Surg Obes Relat Dis 2015; 11: 1020–1023.
    1. Chan JC, Liu HS, Kho BC, et al.. Pattern of thyroid autoimmunity in Chinese patients with pernicious anemia. Am J Med Sci 2009; 337: 432–437.
    1. Kalkan C, Soykan I. Polyautoimmunity in autoimmune gastritis. Eur J Intern Med 2016; 31: 79–83.
    1. De Block CE, De Leeuw IH, Bogers JJ, et al.. Helicobacter pylori, parietal cell antibodies and autoimmune gastropathy in type 1 diabetes mellitus. Aliment Pharmacol Ther 2002; 16: 281–289.
    1. De Block CE, De Leeuw IH, Van Gaal LF. High prevalence of manifestations of gastric autoimmunity in parietal cell antibody-positive type 1 (insulin-dependent) diabetic patients. The Belgian Diabetes Registry. J Clin Endocrinol Metab 1999; 84: 4062–4067.
    1. De Block CE, De Leeuw IH, Van Gaal LF. Autoimmune gastritis in type 1 diabetes: a clinically oriented review. J Clin Endocrinol Metab 2008; 93: 363–371.
    1. Levine SA, Ladd WS. Pernicious anemia: a clinical study of one-hundred and fifty consecutive cases with special reference to gastric anacidity. Bull Johns Hopkins Hosp 1921; 32: 254–266.
    1. Delva PL, Macdonell JE, Macintosh OC. MEGALOBLASTIC ANEMIA OCCURRING SIMULTANEOUSLY IN WHITE FEMALE MONOZYGOTIC TWINS. Can Med Assoc J 1965; 92: 1129–1131.
    1. Lenti MV, Miceli E, Cococcia S, et al.. Determinants of diagnostic delay in autoimmune atrophic gastritis. Aliment Pharmacol Ther 2019; 50: 167–175.
    1. Arango MT, Perricone C, Kivity S, et al.. HLA-DRB1 the notorious gene in the mosaic of autoimmunity. Immunol Res 2017; 65: 82–98.
    1. Chlumská A, Boudová L, Benes Z, et al.. Autoimmune gastritis. A clinicopathologic study of 25 cases. Cesk Patol 2005; 41: 137–142.
    1. Solcia E, Fiocca R, Villani L, et al.. Hyperplastic, dysplastic, and neoplastic enterochromaffin-like-cell proliferations of the gastric mucosa. Classification and histogenesis. Am J Surg Pathol 1995; 19(Suppl. 1): S1–S7.
    1. Stolte M, Bethke B, Rühl G, et al.. Omeprazole-induced pseudohypertrophy of gastric parietal cells. Z Gastroenterol 1992; 30: 134–138.
    1. Claeys D, Faller G, Appelmelk BJ, et al.. The gastric H+, K+-ATPase is a major autoantigen in chronic Helicobacter pylori gastritis with body mucosa atrophy. Gastroenterology 1998; 115: 340–347.
    1. Eidt S, Oberhuber G, Schneider A, et al.. The histopathological spectrum of type A gastritis. Pathol Res Pract 1996; 192: 101–106.
    1. Fong T-L, Dooley CP, Dehesa M, et al.. Helicobacter pylori infection in pernicious anemia: a prospective controlled study. Gastroenterology 1991; 100: 328–332.
    1. Amedei A, Bergman MP, Appelmelk BJ, et al.. Molecular mimicry between Helicobacter pylori antigens and H+, K+–adenosine triphosphatase in human gastric autoimmunity. J Exp Med 2003; 198: 1147–1156.
    1. Lahner E, Annibale B. Pernicious anemia: new insights from a gastroenterological point of view. World J Gastroenterol 2009; 15: 5121–5128.
    1. De Re V, Repetto O, De Zorzi M, et al.. Polymorphism in toll-like receptors and Helicobacter pylori motility in autoimmune atrophic gastritis and gastric cancer. Cancers 2019; 11: 648.
    1. Furuta T, Baba S, Yamade M, et al.. High incidence of autoimmune gastritis in patients misdiagnosed with two or more failures of H. Pylori eradication. Aliment Pharmacol Ther 2018; 48: 370–377.
    1. Miceli E, Lenti MV, Padula D, et al.. Common features of patients with autoimmune atrophic gastritis. Clin Gastroenterol Hepatol 2012; 10: 812–814.
    1. Buxbaum JL, Hormozdi D, Dinis-Ribeiro M, et al.. Narrow-band imaging versus white light versus mapping biopsy for gastric intestinal metaplasia: a prospective blinded trial. Gastrointest Endosc 2017; 86: 857–865.
    1. Shah SC, Kuipers EJ, Li D.American Gastroenterological Association clinical practice update on the diagnosis and management of atrophic gastritis: expert review. Gastroenterology 2021. In Press.
    1. Rugge M, Meggio A, Pennelli G, et al.. Gastritis staging in clinical practice: the OLGA staging system. Gut 2007; 56: 631–636.
    1. Capelle LG, de Vries AC, Haringsma J, et al.. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc 2010; 71: 1150–1158.
    1. Dixon MF, Genta RM, Yardley JH, et al.. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20: 1161–1181.
    1. Coati I, Fassan M, Farinati F, et al.. Autoimmune gastritis: pathologist’s viewpoint. World J Gastroenterol 2015; 21: 12179–12189.
    1. Lenti MV, Rugge M, Lahner E, et al.. Autoimmune gastritis. Nat Rev Dis Primers 2020; 6: 56.
    1. Isajevs S, Liepniece-Karele I, Janciauskas D, et al.. Gastritis staging: interobserver agreement by applying OLGA and OLGIM systems. Virchows Arch 2014; 464: 403–407.
    1. Banks M, Graham D, Jansen M, et al.. British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. Gut 2019; 68: 1545–1575.
    1. Pimentel-Nunes P, Libanio D, Marcos-Pinto R, et al.. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy 2019; 51: 365–388.
    1. Rusak E, Chobot A, Krzywicka A, et al.. Anti—parietal cell antibodies—diagnostic significance. Adv Med Sci 2016; 61: 175–179.
    1. Bizzaro N, Antico A. Diagnosis and classification of pernicious anemia. Autoimmun Rev 2014; 13: 565–568.
    1. Snow CF. Laboratory diagnosis of vitamin B12 and folate deficiency: a guide for the primary care physician. Arch Intern Med 1999; 159: 1289–1298.
    1. Toh BH. Diagnosis and classification of autoimmune gastritis. Autoimmun Rev 2014; 13: 459–462.
    1. Conti L, Lenti MV, Di Sabatino A, et al.. Seronegative autoimmune atrophic gastritis is more common in elderly patients. Dig Liver Dis 2020; 52: 1310–1314.
    1. Antico A, Tampoia M, Villalta D, et al.. Clinical usefulness of the serological gastric biopsy for the diagnosis of chronic autoimmune gastritis. Clin Dev Immunol 2012; 2012: 520970.
    1. Khan S, Del-Duca C, Fenton E, et al.. Limited value of testing for intrinsic factor antibodies with negative gastric parietal cell antibodies in pernicious anaemia. J Clin Pathol 2009; 62: 439–441.
    1. Zagari RM, Rabitti S, Greenwood DC, et al.. Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis. Aliment Pharmacol Ther 2017; 46: 657–667.
    1. Huang R, Park S, Shen J, et al.. Pepsinogens and gastrin demonstrate low discrimination for gastric precancerous lesions in a multi-ethnic United States Cohort. Clin Gastroenterol Hepatol. Epub ahead of print 10 January 2021. DOI: 10.1016/j.cgh.2021.01.009.
    1. Miceli E, Padula D, Lenti MV, et al.. A laboratory score in the diagnosis of autoimmune atrophic gastritis: a prospective study. J Clin Gastroenterol 2015; 49: e1–e5.
    1. Carabotti M, Lahner E, Esposito G, et al.. Upper gastrointestinal symptoms in autoimmune gastritis: a cross-sectional study. Medicine 2017; 96: e5784.
    1. Kalkan C, Soykan I. Differences between older and young patients with autoimmune gastritis. Geriatr Gerontol Int 2017; 17: 1090–1095.
    1. Tenca A, Massironi S, Pugliese D, et al.. Gastro-esophageal reflux and antisecretory drugs use among patients with chronic autoimmune atrophic gastritis: a study with pH-impedance monitoring. Neurogastroenterol Motil 2016; 28: 274–280.
    1. Chen X, Wang R, Huang X, et al.. The level of serum pepsinogen in diagnosing and evaluating the severity of subacute combined degeneration due to vitamin B12 deficiency. Front Neurol 2021; 12: 604523.
    1. Lenti MV, Miceli E, Padula D, et al.. Infertility and recurrent miscarriage in a patient with autoimmune atrophic gastritis. Intern Emerg Med 2018; 13: 815–816.
    1. Zhu Q, Xu QH, Xie T, et al.. Recent insights into the impact of immune dysfunction on reproduction in autoimmune thyroiditis. Clin Immunol 2021; 224: 108663.
    1. Stabler SP. Vitamin B12 deficiency. N Engl J Med 2013; 368: 149–160.
    1. Lenti MV, Lahner E, Bergamaschi G, et al.. Cell blood count alterations and patterns of anaemia in autoimmune atrophic gastritis at diagnosis: a multicentre study. J Clin Med 2019; 8: 1992.
    1. Villanacci V, Casella G, Lanzarotto F, et al.. Autoimmune gastritis: relationships with anemia and Helicobacter pylori status. Scand J Gastroenterol 2017; 52: 674–677.
    1. Elloumi H, Sabbah M, Debbiche A, et al.. Systematic gastric biopsy in iron deficiency anaemia. Arab J Gastroenterol 2017; 18: 224–227.
    1. Lahner E, Norman GL, Severi C, et al.. T1077 occurrence of intrinsic factor and parietal cell autoantibodies in atrophic body gastritis patients with or without pernicious anemia. Gastroenterology 2008; 134: A-478.
    1. Hershko C, Ronson A, Souroujon M, et al.. Variable hematologic presentation of autoimmune gastritis: age-related progression from iron deficiency to cobalamin depletion. Blood 2006; 107: 1673–1679.
    1. Zilli A, Cavalcoli F, Ciafardini C, et al.. Deficiency of micronutrients in patients affected by chronic atrophic autoimmune gastritis: a single-institution observational study. Dig Liver Dis 2019; 51: 505–509.
    1. Lahner E, Centanni M, Agnello G, et al.. Occurrence and risk factors for autoimmune thyroid disease in patients with atrophic body gastritis. Am J Med 2008; 121: 136–141.
    1. Zelissen PM, Bast EJ, Croughs RJ. Associated autoimmunity in Addison’s disease. J Autoimmun 1995; 8: 121–130.
    1. Kahaly GJ, Hansen MP. Type 1 diabetes associated autoimmunity. Autoimmun Rev 2016; 15: 644–648.
    1. Rodriguez-Castro KI, Franceschi M, Miraglia C, et al.. Autoimmune diseases in autoimmune atrophic gastritis. Acta Biomed 2018; 89: 100–103.
    1. Rustgi N, Shroff SG, Katona BW. Two types of gastric cancer caused by the same underlying condition. Gastroenterology 2018; 154: 1246–1248.
    1. Lahner E, Esposito G, Pilozzi E, et al.. Occurrence of gastric cancer and carcinoids in atrophic gastritis during prospective long-term follow up. Scand J Gastroenterol 2015; 50: 856–865.
    1. Mahmud N, Stashek K, Katona BW, et al.. The incidence of neoplasia in patients with autoimmune metaplastic atrophic gastritis: a renewed call for surveillance. Ann Gastroenterol 2019; 32: 67–72.
    1. Borch K. Epidemiologic, clinicopathologic, and economic aspects of gastroscopic screening of patients with pernicious anemia. Scand J Gastroenterol 1986; 21: 21–30.
    1. Rugge M, Fassan M, Pizzi M, et al.. Autoimmune gastritis: histology phenotype and OLGA staging. Aliment Pharmacol Ther 2012; 35: 1460–1466.
    1. Murphy G, Dawsey SM, Engels EA, et al.. Cancer risk after pernicious anemia in the US elderly population. Clin Gastroenterol Hepatol 2015; 13: 2282–2289.
    1. Ye W, Nyren O. Risk of cancers of the oesophagus and stomach by histology or subsite in patients hospitalised for pernicious anaemia. Gut 2003; 52: 938–941.
    1. Song M, Latorre G, Ivanovic-Zuvic D, et al.. Autoimmune diseases and gastric cancer risk: a systematic review and meta-analysis. Cancer Res Treat 2019; 51: 841–850.
    1. Vannella L, Lahner E, Osborn J, et al.. Systematic review: gastric cancer incidence in pernicious anaemia. Aliment Pharmacol Ther 2013; 37: 375–382.
    1. ASGE Standards of Practice Committee, Evans JA, Chandrasekhara V, et al.. The role of endoscopy in the management of premalignant and malignant conditions of the stomach. Gastrointest Endosc 2015; 82: 1–8.
    1. Lahner E, Zagari RM, Zullo A, et al.. Chronic atrophic gastritis: natural history, diagnosis and therapeutic management. A position paper by the Italian Society of Hospital Gastroenterologists and Digestive Endoscopists [AIGO], the Italian Society of Digestive Endoscopy [SIED], the Italian Society of Gastroenterology [SIGE], and the Italian Society of Internal Medicine [SIMI]. Dig Liver Dis 2019; 51: 1621–1632.
    1. Sugano K, Tack J, Kuipers EJ, et al.. Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015; 64: 1353–1367.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever